The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
In the 2008 World Health Organization-sponsored classification of hematopoietic and lymphoid malignancies, changes were made in the classification and criteria for the diagnosis of some of the myeloproliferative disorders. These changes were initiated by recent insights into the molecular pathogenesis of these disorders. In this article, the changes made to the myeloproliferative neoplasm and the basis of the new classification and altered diagnostic criteria are summarized and discussed.
Anastasi
John
J
Department of Pathology, University of Chicago, Chicago, IL 60637, USA. john.anastasi@uchospitals.edu
D019337:Hematologic Neoplasms / Q000145:classification* / Q000175:diagnosis / Q000235:genetics; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000145:classification* / Q000175:diagnosis / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics; D014944:World Health Organization
D011505:Protein-Tyrosine Kinases; D053614:Janus Kinase 2